VERTEX PHARMACEUTICALS INC / MA Payments of Financing Costs
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Payments of Financing Costs of $10.64 million for the 6-month period ending 2017-06-30, per its 10-Q filed 2017-07-28.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfFinancingCosts · last filed 2017-07-28
- VERTEX PHARMACEUTICALS INC / MA payments of financing costs for the quarter ending 2017-06-30 was $5.93M, a 69.69% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA payments of financing costs for the quarter ending 2017-03-31 was $4.70M, a 16.38% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA payments of financing costs for the quarter ending 2016-09-30 was $5.79M, a 179.27% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA payments of financing costs for the quarter ending 2016-06-30 was $3.50M, a 64.83% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA payments of financing costs for fiscal 2014 was -$8.05M.
- VERTEX PHARMACEUTICALS INC / MA payments of financing costs for fiscal 2013 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA payments of financing costs for fiscal 2012 was $0.00.
| Period end | Payments of Financing Costs 3 month | Payments of Financing Costs 3 month as first filed | Payments of Financing Costs 6 month | Payments of Financing Costs 6 month as first filed | Payments of Financing Costs 9 month | Payments of Financing Costs 9 month as first filed | Payments of Financing Costs 12 month |
|---|---|---|---|---|---|---|---|
| 2017-06-30 | $5.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-28 | $10.64M 10-Q · filed 2017-07-28 | |||||
| 2017-03-31 | $4.70M 10-Q · filed 2017-04-28 | ||||||
| 2016-09-30 | $5.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-31 | $9.29M derived: sum of 2 quarters · filed 2017-07-28 | $13.33M 10-Q · filed 2016-10-31 | ||||
| 2016-06-30 | $3.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-28 | $7.54M 10-Q · filed 2017-07-28 | |||||
| 2016-03-31 | $4.04M 10-Q · filed 2017-04-28 | ||||||
| 2015-09-30 | $2.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-31 | $12.02M derived: sum of 2 quarters · filed 2016-10-31 | $16.52M 10-Q · filed 2016-10-31 | -$8.75M derived: sum of 4 quarters · filed 2016-10-31 | |||
| 2015-06-30 | $9.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-01 | $14.44M 10-Q · filed 2016-08-01 | -$10.82M derived: sum of 3 quarters · filed 2016-08-01 | -$5.49M derived: sum of 4 quarters · filed 2016-08-01 | |||
| 2015-03-31 | $4.50M 10-Q · filed 2016-05-03 | -$20.77M derived: sum of 2 quarters · filed 2016-05-03 | -$15.44M derived: sum of 3 quarters · filed 2016-05-03 | -$6.17M derived: sum of 4 quarters · filed 2016-05-03 | |||
| 2014-12-31 | -$25.27M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-13 | -$19.93M derived: sum of 2 quarters · filed 2015-10-30 | -$10.67M derived: sum of 3 quarters · filed 2015-10-30 | -$8.05M 10-K · filed 2015-02-13 | |||
| 2014-09-30 | $5.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-30 | $14.59M derived: sum of 2 quarters · filed 2015-10-30 | $17.21M 10-Q · filed 2015-10-30 | -$8.05M 10-Q · filed 2014-11-06 | $17.21M derived: sum of 4 quarters · filed 2015-10-30 | ||
| 2014-06-30 | $9.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-04 | $11.88M 10-Q · filed 2015-08-04 | -$8.05M 10-Q · filed 2014-07-31 | $11.88M derived: sum of 3 quarters · filed 2015-08-04 | $11.88M derived: sum of 4 quarters · filed 2015-08-04 | ||
| 2014-03-31 | $2.62M 10-Q · filed 2015-05-04 | -$8.05M 10-Q · filed 2014-05-05 | $2.62M derived: sum of 2 quarters · filed 2015-05-04 | $2.62M derived: sum of 3 quarters · filed 2015-05-04 | $2.62M derived: sum of 4 quarters · filed 2015-05-04 | ||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-13 | $0.00 derived: sum of 2 quarters · filed 2015-02-13 | $0.00 derived: sum of 3 quarters · filed 2015-02-13 | $0.00 10-K · filed 2015-02-13 | |||
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $0.00 derived: sum of 2 quarters · filed 2014-11-06 | $0.00 10-Q · filed 2014-11-06 | ||||
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-31 | $0.00 10-Q · filed 2014-07-31 | |||||
| 2013-03-31 | $0.00 10-Q · filed 2014-05-05 | ||||||
| 2012-12-31 | $0.00 10-K · filed 2015-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |